brahms-logo
Search

  
Advanced Search


News
ProHOSP study demonstrates the value of Procalcitonin marker for lower respiratory tract infections
See here presentations from 29th ISICEM, March 2009: Using procalcitonin to guide antibiotic therapy
NewsArchiv


Quicklinks


Introduction Sepsis
PCT - Assays
B·R·A·H·M·S GmbH
International Sepsis Forum

News Archiv
ProHOSP study demonstrates the value of Procalcitonin marker for lower respiratory tract infections
A reduction in the use of antibiotics to a third, lower antibiotic prescriptions and fewer side effects without negative implications for the patients:
11/5/2009
See here presentations from 29th ISICEM, March 2009: Using procalcitonin to guide antibiotic therapy

7/6/2009
Shorter treatment duration and shorter stay in ICU after PCT-guided antibiotic therapy
Am J Respir Crit Care Med Vol 177. pp 498 - 505, 2008
4/11/2008
SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS AND B·R·A·H·M·S AKTIENGESELLSCHAFT AGREE TO DEVELOP PCT
New Assay Targeted for Siemens ADVIA Centaur and Immulite Family of Immunoassay Analyzers
4/11/2008
Procalcitonin guidance in AECOPD significantly reduces antibiotic exposure up to 6 months
CHEST, January 2007
10/23/2007
bioMérieux Launches VIDAS® B·R·A·H·M·S PCT, a Procalcitonin Measurement Test for VIDAS system
03/30/2007. bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of VIDAS® B·R·A·H·M·S PCT. This new, CE approved test, was developed following the licensing agreement signed with B·R·A·H·M·S. The test is sensitive and specific, used in the early detection of severe bacterial infections (e.g. sepsis).
4/2/2007
Roche Diagnostics and BRAHMS announce agreement of a global licence and cooperation on Procalcitonin
Basel, November 6th, 2006: BRAHMS Corporation will itself exercise exclusively the distribution rights in relevant European markets for the product manufactured by Roche Diagnostics under licence. Roche Diagnostics will serve in particular the markets outside Europe for the test which has regulatory approvals in Japan and the U.S.
2/19/2007
B·R·A·H·M·S AG and bioMérieux SA sign a non-exclusive agreement on the use of Procalcitonin
Marcy l´Etoile, March 1st, 2005: B·R·A·H·M·S AG and bioMérieux SA have announced the signature of a non-exclusive agreement on the use of Procalcitonin as a diagnostic marker for severe bacterial infections.
4/10/2006
B·R·A·H·M·S receives final FDA clearance to market Procalcitonin (PCT)
Atlanta, GA - Feb. 21, 2005 B·R·A·H·M·S Diagnostica, LLC announces receipt of final notification of market clearance in the U.S. for its inflammatory response marker in sepsis, B·R·A·H·M·S PCT LIA.
3/16/2006
 Contact | Imprint | Chinese Version